Skip to main content
See every side of every news story
Published loading...Updated

Rentokil Initial H2 Earnings Call Highlights

Belite Bio aims for U.S. launch of tinlarebant in early 2027 after Phase III trial showed 36% lesion growth reduction in Stargardt disease, with NDA filing planned for Q2 2026.

Summary
Rentokil Initial (NYSE:RTO) executives told investors the company saw “encouraging progress” in 2025, led by improving performance in North America during the second half of the year and continued margin expansion at the group level. Management emphasized that revised commercial initiatives, a broad

6 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

CNBC broke the news in United States on Tuesday, March 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal